Karuna Therapeutics Inc. (NASDAQ:KRTX) Recent Earnings Shows Major Promise

Karuna Therapeutics Inc. (NASDAQ:KRTX) Recent Earnings Shows Major Promise


The Karuna Therapeutics Inc. (KRTX) shares are trading at higher $108.62 and the avg recommendation for the stock is Strong Buy. The current analyst price target stands at $126.40.

To add more color to this target, the company’s high over the last year is $152.00 and the low is $11.24. Over the last 52 weeks, KRTX is down -28.54% while the S&P 500 is down -2.55%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In addition, KRTX has free cash flow of -$8.42 million as of 03-2020 The company’s EBITDA came in at -$10.03 million which compares well with its peers.

KRTX Return on Equity (ROE) is -18.20%, and its Return on Assets is -15.80%. All told, it is clear that, KRTX needs to be on your watchlist.

Find out when KRTX reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. KRTX has a short ratio of 4.08 and outstanding shares of 26.04M.

Company Outlook

KRTX has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.39 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.66. Karuna Therapeutics Inc. KRTX also noted assets of $389.72 million at the end of the last quarter. Investors should also keep an eye on sector updates as KRTX has historically followed its peers on positive news.

All told, Karuna Therapeutics Inc. KRTX has strung together solid data and demonstrated underlying fundamentals. At its current valuation, KRTX represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Karuna Therapeutics Inc. KRTX is now commanding a market cap of 2.91B and a float of 21.18M. KRTX is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of KRTX stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in KRTX, either long or short, and we have not been compensated for this article.